# OnCo record serplulimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/serplulimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "serplulimab" ;
  schema:name "Serplulimab"@en ;
  schema:description "Serplulimab is a Chinese PD-1 antibody with the largest survival gain of any first-line small-cell lung cancer immunotherapy trial, approved in China, Europe, and the UK but not yet the US."@en ;
  schema:url <https://onco.cc/drugs/serplulimab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Serplulimab>, <https://www.nice.org.uk/guidance/ta1167> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Hansizhuang / Hetronifly" ;
  onco:approval "China 2022: First-line ES-SCLC with chemotherapy", "EU 2025: First-line ES-SCLC with carboplatin-etoposide", "England (NICE) 2026: Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/henlius/> ;
  onco:terms <https://onco.cc/terms/limited-extensive-stage/> ;
  onco:trials <https://onco.cc/trials/astrum-005/>, <https://onco.cc/trials/nct05353257/>, <https://onco.cc/trials/nct04547166/>, <https://onco.cc/trials/nct05468489/>, <https://onco.cc/trials/nct07253142/>, <https://onco.cc/trials/nct07269782/>, <https://onco.cc/trials/nct06848699/>, <https://onco.cc/trials/nct06349980/>, <https://onco.cc/trials/nct05787613/> .